Inamed rejects mergers and repurchases stock:
This article was originally published in Clinica
Executive Summary
Breast implant manufacturer Inamed has finished evaluating its strategic options - a process it began in early October - and plans to resume a $25 million stock repurchase programme. The company had received several enquiries regarding a merger (see Clinica No 930, p 11), but has now concluded that the indicated price ranges were insufficient. The Santa Barbara, California company had suspended the stock repurchase programme, which was authorised in September, pending the outcome of the evaluation process.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.